BIO stock forecast, quote, news & analysis
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets... Show more
Why Bio-Rad Laboratories (BIO) Is Down -9% in the Last 30 Days
Key Takeaways
- BIO stock declined -9% over the past 30 days, driven primarily by a Q1 2026 earnings miss and lowered full-year guidance on weakening end-market demand.
- Over the past quarter, the stock fell -15%, reflecting sustained challenges including prior earnings disappointment and segment sales declines.
- Key factors include currency-neutral sales drops, reduced operating margin outlook, and broader life sciences sector pressures.
- Volatile trading with sharp post-earnings drops amid analyst scrutiny on revenue growth.
- Investors monitoring recovery in life science and clinical diagnostics segments.
Bio-Rad Laboratories (BIO) Company Overview and Market Position
Bio-Rad Laboratories, Inc. (BIO) is a global leader in life science research and clinical diagnostics products. The company develops, manufactures, and markets a broad range of innovative instruments, software, consumables, and test systems used in research, healthcare, food safety, and environmental quality testing. Operating through two main segments—Life Science and Clinical Diagnostics—BIO supports applications from basic research to applied testing solutions.
Bio-Rad holds a strong competitive position in biotechnology tools and diagnostics, competing with firms like Thermo Fisher Scientific and Danaher. Its fundamentals, including recurring revenue from consumables, provide stability, but recent exposure to softening demand in research funding and diagnostics has pressured stock performance amid economic uncertainties.
Bio-Rad Laboratories (BIO) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, BIO stock declined approximately -9%, moving from around $278 per share to $253. The movement was volatile, with a steady range in early April giving way to a sharp drop following recent earnings, reflecting trend-driven selling pressure.
In the past quarter, the stock fell -15%, from roughly $298 to $253. Performance was range-bound initially with fluctuations between $270-$300, punctuated by significant declines tied to corporate updates, indicating broader downward momentum amid heightened volatility.
What Drove BIO Stock Price in the Last 30 Days
The primary catalyst for BIO's -9% decline over the past 30 days was the Q1 2026 earnings release on April 30, where the company reported EPS (earnings per share) of $1.89, missing consensus estimates of $1.97. Currency-neutral sales fell 4.2% across both segments, signaling persistent weakness in end markets.
Bio-Rad lowered its full-year 2026 operating margin guidance to 10%-12% from the prior 12%-12.5%, citing ongoing challenges. This disappointed investors, triggering a sharp post-earnings sell-off. Market sentiment shifted negatively as the results highlighted slower recovery in life science research demand and clinical diagnostics volumes. Broader sector trends, including budget constraints in biotech research, amplified the impact, leading to increased selling pressure.
What Drove BIO Stock Performance Over the Last Quarter
Over the quarter, BIO's -15% drop stemmed from cumulative earnings pressures and segment headwinds. The Q4 2025 results in February also missed expectations with EPS of $2.51 versus $2.65 anticipated, contributing to an early sharp decline from above $290 to the mid-$250s.
Sustained sales softness in the Life Science segment, driven by reduced research spending, and moderating growth in Clinical Diagnostics amid reimbursement dynamics weighed heavily. Macroeconomic factors like elevated interest rates curbing R&D (research and development) investments and currency fluctuations exacerbated declines. Institutional flows showed caution, with trading volumes spiking on negative updates, underscoring investor concerns over near-term growth trajectory.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing and most relevant AI-driven trading bots from its extensive library of hundreds of bots actively trading thousands of tickers across various markets. These bots employ diverse strategies, including trend-following, mean reversion, momentum, and pattern recognition, optimized for different timeframes from intraday to long-term holds. Performance metrics such as win rate, profit factor, and Sharpe ratio are transparently displayed, helping users identify bots aligned with their risk tolerance and market views. Curated based on recent success and relevance, the section highlights bots excelling in current conditions. Explore Trending AI Robots to discover automated trading solutions tailored for stocks like BIO.
BIO Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor upcoming Q2 2026 earnings for updates on sales recovery and margin progression. Key industry trends include biotech funding cycles and diagnostics demand amid healthcare policy shifts. Macro environment factors like interest rate trajectories and global economic growth will influence R&D spending.
Strategic developments such as new product launches or partnerships in high-growth areas like next-generation sequencing could act as catalysts. Risks include further end-market weakness, currency volatility, and competitive pressures. Sentiment may hinge on management's commentary around demand stabilization.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
BIO in upward trend: price rose above 50-day moving average on May 18, 2026
BIO moved above its 50-day moving average on May 18, 2026 date and that indicates a change from a downward trend to an upward trend. In of 46 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on May 18, 2026. You may want to consider a long position or call options on BIO as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BIO just turned positive on May 18, 2026. Looking at past instances where BIO's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for BIO crossed bullishly above the 50-day moving average on May 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIO advanced for three days, in of 315 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for BIO moved out of overbought territory on June 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 64 cases where BIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
BIO broke above its upper Bollinger Band on May 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BIO entered a downward trend on May 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.138) is normal, around the industry mean (10.859). P/E Ratio (48.471) is within average values for comparable stocks, (61.865). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.719). BIO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (3.040) is also within normal values, averaging (26.556).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of life science research products and clinical diagnostics
Industry MedicalNursingServices